Biological prognostic factors in adult soft tissue sarcomas

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4519-4526

  Ottaiano, Alessandro ^a   De Chiara, Anna ^a   Fazioli, Flavio ^a   Talamanca, Annarita Aiello ^a   Mori, Stefano ^a   Botti, Gerardo ^a   Milano, Amalia ^a   Apice, Gaetano ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Prognostic factors; Review; Soft tissue sarcomas

Indexed keywords

BETA CATENIN; CD40 ANTIGEN; CYCLINE; GENE PRODUCT; GLYCOPROTEIN P; HYBRID PROTEIN; LEUCINE ZIPPER PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN NM23 H2; PROTEIN P27; PROTEIN P53; PROTEIN SSX1; PROTEIN SSX2; PROTEIN TLS CHOP; S PHASE KINASE ASSOCIATED PROTEIN 2; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ADULT; BONE METASTASIS; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; GENE EXPRESSION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITY CONTROL; QUESTIONNAIRE; REVIEW; SOFT TISSUE METASTASIS; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW;

ADULT; HUMANS; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 28444442575     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Weiss SW and Goldblum JR: Enzinger and Weiss's Soft Tissue Tumors. 4th ed. St. Louis, Mo: Mosby, 2001.
2. Komdeur R, Hoekstra HJ, van den Berg E et al: Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. Cancer Metastasis Rev 21: 167-183, 2002.
3. Maltoni M and Amadori D: Prognosis in advanced cancer. Hematol Oncol Clin North Am 16: 715-729, 2002.
4. Montserrat E: Prognostic factors in aggressive lymphoma: the contribution of novel biological markers. Ann Hematol 80: B42-44, 2001.
5. Gospodarowicz M, Mackillop W, O'Sullivan B et al: Prognostic factors in clinical decision making: the future. Cancer 91: 1688-1695, 2001.
6. Yamauchi H, Stearns V and Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334-2356, 2001.
7. Gospodarowicz M and O'Sullivan B: Prognostic factors in cancer. Semin Surg Oncol 21: 13-18, 2003.
8. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M (eds.): Soft tissue sarcoma. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, pp. 193-197, 2002.
9. Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1: 199-206, 1990.
10. Levine EA, Holzmayer T, Bacus S et al: Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 15: 3249-3257, 1997.
11. Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM and Brennan MF: Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 83: 490-497, 1998.
12. Huuhtanen RL, Blomqvist CP, Wiklund TA et al: Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma. Br J Cancer 79: 945-951, 1999.
13. Skytting BT, Bauer HC, Perfekt R, Nilsson G and Larsson O: Ki-67 is strongly prognostic in synovial sarcoma: analysis based on 86 patients from the Scandinavian Sarcoma Group Register. Br J Cancer 80: 1809-1814, 1999.
14. Hoos A, Stojadinovic A, Mastorides S et al: High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 92: 869-874, 2001.
15. Maga G and Hubscher U: Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 116: 3051-3060, 2003.
16. Hall PA, Levison DA, Woods AL et al: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294, 1990.
17. Oda Y, Hashimoto H, Takeshita S and Tsuneyoshi M: The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer 72: 478-485, 1993.
18. Dreinhofer KE, Akerman M, Willen H, Anderson C, Gustafson P and Rydholm A: Proliferating cell nuclear antigen (PCNA) in high-grade malignant fibrous histiocytoma: prognostic value in 48 patients. Int J Cancer 59: 379-382, 1994.
19. Gustafson P, Willen H, Baldetorp B, Ferno M, Akerman M and Rydholm A: Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer 70: 114-119, 1992.
20. Kuratsu S, Tomita Y, Myoui A, Uchida A, Ono K and Aozasa K: DNA ploidy pattern and cell cycle stage of tumor cells in soft-tissue sarcomas: clinical implications. Oncology 52: 363-370, 1995.
21. Huuhtanen RL, Blomqvist CP, Wiklund TA, Virolainen MJ, Elomaa AI, Pan Y and Tribukait B: S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome. Cancer 77: 1815-1822, 1996.
22. Wijnaendts LC, van der Linden JC, van Diest P et al: Prognostic importance of DNA flow cytometric variables in rhabdomyosarcomas. J Clin Pathol 46: 948-952, 1993.
23. De Zen L, Sommaggio A, d'Amore ES et al: Clinical relevance of DNA ploidy and proliferative activity in childhood rhabdomyosarcoma: a retrospective analysis of patients enrolled onto the Italian Cooperative Rhabdomyosarcoma Study RMS88. J Clin Oncol 15: 1198-1205, 1997.
24. Gustafson P, Ferno M, Akerman M et al: Flow cytometric S-phase fraction in soft-tissue sarcoma: prognostic importance analysed in 160 patients. Br J Cancer 75: 94-100, 1997.
25. Collin F, Chassevent A, Bonichon F, Bertrand G, Terrier P and Coindra JM: Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. French Federation of Cancer Centers (FNCLCC) Sarcoma Group. Cancer 79: 2371-2379, 1997.
26. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
27. Sigal A and Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788-6793, 2000.
28. Kaelin WG Jr: The emerging p53 gene family. J Natl Cancer Inst 91: 594-598, 1999.
29. Kawai A, Noguchi M, Beppu Y et al: Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer 3: 2499-2505, 1994.
30. Antonescu CR, Tschernyavsky SJ, Decuseara R et al: Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 7: 3977-3987, 2001.
31. Tang QQ and Lane MD: Role of C/EBP homologous protein (CHOP-10) in the programmed activation of CCAAT/enhancer-binding protein-beta during adipogenesis. Proc Natl Acad Sci USA 97: 12446-12450, 2000.
32. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA et al: Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 19: 6015-6022, 2000.
33. Stacey DW: Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 15: 158-163, 2003.
34. Lamb J and Ewen ME: Cyclin D1 and molecular chaperones: implications for tumorigenesis. Cell Cycle 2: 525-527, 2003.
35. Kim SH, Cho NH, Tallini G, Dudas M, Lewis JJ and Cordon-Cardo C: Prognostic role of cyclin D1 in retroperitoneal sarcomas. Cancer 91: 428-434, 2001.
36. Kim SH, Lewis JJ, Brennan MF, Woodruff JM, Dudas M and Cordon-Cardo C: Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res 4: 2377-2382, 1998.
37. Wurl P, Kappler M, Meye A et al: Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 359: 943-945, 2002.
38. Nicol Keith W, Jeffry Evans TR and Glasspool RM: Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 195: 404-414, 2001.
39. Barr FG: Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20: 5736-5746, 2001.
40. Sorensen PH, Lynch JC, Qualman SJ et al: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20: 2672-2679, 2002.
41. Ladanyi M: Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 20: 5755-5762, 2001.
42. Ladanyi M, Antonescu CR, Leung DH et al: Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 62: 135-140, 2002.
43. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
44. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M and Kimura T: Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84: 1610-1615, 2001.
45. Brackenbury R: Molecular mechanisms of cell adhesion in normal and transformed cells. Cancer Metastasis Rev 4: 41-58, 1985.
46. Berx G and Van Roy F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293, 2001.
47. Bremnes RM, Veve R, Hirsch FR and Franklin WA: The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 36: 115-124, 2002.
48. Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487, 2004.
49. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
50. Michaelson JS and Leder P: Beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 20: 5093-5099, 2001.
51. van de Wetering M, Sancho E, Verweij C et al: The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250, 2002.
52. Saito T, Oda Y, Sakamoto A et al: Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 192: 342-350, 2000.
53. Salerno M, Ouatas T, Palmieri D and Steeg PS: Inhibition of signal transduction by the nm23 metastasis suppressor: possible mechanisms. Clin Exp Metastasis 20: 3-10, 2003.
54. Royds JA, Robinson MH, Stephenson TJ, Rees RC and Fisher C: The association between nm23 gene expression and survival in patients with sarcomas. Br J Cancer 75: 1195-1200, 1997.
55. Pagano M: Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell 14: 414-416, 2004.
56. Lin DI and Alan Diehl J: Mechanism of cell-cycle control: ligating the ligase. Trends Biochem Sci 29: 453-455, 2004.
57. Oliveira AM, Okuno SH, Nascimento AG and Lloyd RV: Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 21: 722-727, 2003.
58. Oliveira AM, Nascimento AG, Okuno SH and Lloyd RV: p27(kip1) protein expression correlates with survival in myxoid and round-cell liposarcoma. J Clin Oncol 18: 2888-2893, 2000.
59. Younes A and Kadin ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21: 3526-3534, 2003.
60. Ottaiano A, De Chiara A, Perrone F et al: Prognostic value of CD40 in adult soft tissue sarcomas. Clin Cancer Res 10: 2824-2831, 2004.
61. Bertucci F, Viens P, Tagett R, Nguyen C, Houlgatte R and Birnbaum D: DNA arrays in clinical oncology: promises and challenges. Lab Invest 83: 305-316, 2003.